Who founded Cerecor Inc.?

Cerecor Inc. was founded by Blake M. Paterson in 2011.

Who are Cerecor Inc.'s investors?

Cerecor Inc.'s investors include New Enterprise Associates (NEA), OrbiMed, PETRICHOR SCION THERAPEUTICS.

How much funding has Cerecor Inc. raised?

Cerecor Inc. has disclosed $152.9M raised across 4 rounds.

Where is Cerecor Inc. headquartered?

Cerecor Inc. is headquartered in Baltimore, US.

Cerecor Inc.

also invests · investor profile

Baltimore, US · Founded 2011 · 51 employees on LinkedIn · 3 known investors

Find your way into Cerecor Inc.

393 people in our graph share verified history with the Cerecor Inc. team — schools, employers, funds. One of them is your warm intro.

Josh Kopelmanunlockedknows Federica F. O'Brien · together at Infonautics, Inc. (NASDAQ: INFO) (overlapped)

knows the team · via Nifty's

knows the team · via Alba Therapeutics Corporation

×3knows the team · via Medpace

knows the team · via TELA Bio

knows the team · via National Institute of Mental Health (NIMH)

Avalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Its pipeline includes abdakibart (AVTX-009), tested in a Phase 2 trial for hidradenitis suppurativa, and AVTX-010, a long-acting next-generation anti-IL-1β antibody.

Biotech Medical Devices

Founders & leadership

Cerecor Inc. was founded in 2011 by Blake M. Paterson.

Blake M. PatersonFounder

Mariam Morris ExecutiveExecutive Officer at Cerecor Inc. (which operates Avalo, a clinical-stage biotech company developing therapeutics for immune-mediated inflammatory diseases). Morris has more than 25 years of experience in business strategy, BioPharma operations, SEC reporting, and investor relations.

Ronald Marcus ExecutiveRonald Marcus held leadership positions including CMO at Cerecor and Spinifex, VP of Research and Development at Supernus, CMO at Terran Biosciences, and SVP of Medical at Karuna Therapeutics where he worked on the KarXT antipsychotic program; most recently he was at BMS working on the KarXT lifecycle management program. His background spans drug development across psychiatry, neurology, and pain conditions.

Uli HacksellExecutive

John KaiserExecutive

James Vornov Executive(which operates Avalo, a clinical-stage biotech company developing IL-1β pathway therapeutics). He has held roles in academic research and clinical development at companies of varying sizes, with extensive experience across CNS therapeutic areas including stroke, neurodegeneration, and pain, as well as expertise in adaptive trial design and pharmacokinetic/pharmacodynamic modeling.

Reza MazhariExecutive

Federica F. O'Brien ExecutiveFederica F. O'Brien is an Executive Officer at Cerecor Inc. (which develops Avalo, a clinical-stage biotechnology company focused on IL-1β pathway therapeutics for inflammatory diseases). She has held CFO and COO roles at private and public life sciences and technology companies, and spent 15 years in accounting, audit, tax and consulting roles at PwC and other public accounting firms.

Bernadine Heather FraserExecutive

Sharon Rowland ExecutiveShe has extensive experience in regulatory strategy and investigational product development for biologics, peptides, and small molecules across multiple therapeutic areas, including FDA and EMA interactions, IND filings, and NDA/BLA submissions.

Board

Isaac BlechBoard director

Magnus PerssonBoard director

Investors · 3

New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M

OrbiMedlisted by OrbiMedNew York · $1M – $75M

How we know: OrbiMed's portfolio page · the VCSheet dataset · Not right? Tell us

PETRICHOR SCION THERAPEUTICSinferredNew York

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$152.9M disclosed across 4 rounds · 2014–2024

▶$130.6MraisedApr 2024 · 25 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

June Almenoff, M.D., Ph.D.Director
Mitchell ChanDirector
Jonathan Goldman, M.D.Director
Aaron KantoffDirector
Gilla Kaplan, Ph.D.Director
Magnus Persson, M.D., Ph.D.Director
Samantha TruexDirector
Christopher SullivanExecutive Officer
Garry Neil, M.D.Executive Officer, Director

Offering amount: $200M
Amount sold: $130.6M
Finders' fees: $6.9M
Placement agents: Oppenheimer & Co. Inc.
First sale: Mar 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$5MraisedMay 2017 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

EUGENE A. BAUERDirector
ISAAC BLECHDirector
PHIL GUTRYDirector
MAGNUS PERSSONDirector
ULI HACKSELLExecutive Officer, Director
JOHN KAISERExecutive Officer
THOMAS AASENDirector
MARIAM E MORRISExecutive Officer
RONALD MARCUSExecutive Officer

Offering amount: $5M
Amount sold: $5M
First sale: Apr 2017
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1MraisedSep 2016 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Isaac BlechDirector
Eugene BauerDirector
Phil GutryDirector
Thomas AasenDirector
Mariam MorrisExecutive Officer
Behshad SheldonDirector
Ronald MarcusExecutive Officer
Uli HacksellExecutive Officer, Director
Magnus PerssonDirector
John KaiserExecutive Officer

Offering amount: $15M
Amount sold: $1M
First sale: Sep 2016
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$16.3MraisedJul 2014 · 13 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Magnus PerssonDirector
James VornovExecutive Officer
Isaac BlechDirector
Blake M. PatersonExecutive Officer, Director
Reza MazhariExecutive Officer
Frank TortiDirector
Eugene A. BauerDirector
Federica F. O'BrienExecutive Officer
Bernadine Heather FraserExecutive Officer
Sharon RowlandExecutive Officer
Mayukh SukhatmeDirector
Sol J. BarerDirector
John KaiserExecutive Officer

Offering amount: $33.3M
Amount sold: $16.3M
Finders' fees: $300K
Proceeds to insiders: $755K
Placement agents: Trout Capital LLC
First sale: Jul 2014
Incorporated: Corporation, Delaware, 2011
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Cerecor Inc. do?: Avalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Its pipeline includes abdakibart (AVTX-009), tested in a Phase 2 trial for hidradenitis suppurativa, and AVTX-010, a long-acting next-generation anti-IL-1β antibody.
Who founded Cerecor Inc.?: Cerecor Inc. was founded by Blake M. Paterson in 2011.
Who are Cerecor Inc.'s investors?: Cerecor Inc.'s investors include New Enterprise Associates (NEA), OrbiMed, PETRICHOR SCION THERAPEUTICS.
How much funding has Cerecor Inc. raised?: Cerecor Inc. has disclosed $152.9M raised across 4 rounds.
Where is Cerecor Inc. headquartered?: Cerecor Inc. is headquartered in Baltimore, US.